#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Hippocampal involvement in nonpathological déjà vu: Subfield vulnerability rather than temporal lobe epilepsy equivalent Abstract Introduction Morphological correlates of nonpathological déjà vu (DV) have been identified recently within the human brain.
1-1	0-11	Hippocampal	_
1-2	12-23	involvement	_
1-3	24-26	in	_
1-4	27-42	nonpathological	_
1-5	43-47	déjà	_
1-6	48-50	vu	_
1-7	51-52	:	_
1-8	53-61	Subfield	_
1-9	62-75	vulnerability	_
1-10	76-82	rather	_
1-11	83-87	than	_
1-12	88-96	temporal	_
1-13	97-101	lobe	_
1-14	102-110	epilepsy	_
1-15	111-121	equivalent	_
1-16	122-130	Abstract	_
1-17	131-143	Introduction	_
1-18	144-157	Morphological	_
1-19	158-168	correlates	_
1-20	169-171	of	_
1-21	172-187	nonpathological	_
1-22	188-192	déjà	_
1-23	193-195	vu	_
1-24	196-197	(	_
1-25	198-200	DV	_
1-26	201-202	)	_
1-27	203-207	have	_
1-28	208-212	been	_
1-29	213-223	identified	_
1-30	224-232	recently	_
1-31	233-239	within	_
1-32	240-243	the	_
1-33	244-249	human	_
1-34	250-255	brain	_
1-35	256-257	.	_

Text=Significantly reduced gray matter volume (GMV) within a set of cortical and subcortical regions reported in subjects experiencing DV seems to mirror the distribution of GMV reduction in mesial temporal lobe epilepsy (MTLE) patients but vary in terms of the hippocampus.
2-1	258-271	Significantly	_
2-2	272-279	reduced	_
2-3	280-284	gray	_
2-4	285-291	matter	_
2-5	292-298	volume	_
2-6	299-300	(	_
2-7	301-304	GMV	_
2-8	305-306	)	_
2-9	307-313	within	_
2-10	314-315	a	_
2-11	316-319	set	_
2-12	320-322	of	_
2-13	323-331	cortical	_
2-14	332-335	and	_
2-15	336-347	subcortical	_
2-16	348-355	regions	_
2-17	356-364	reported	_
2-18	365-367	in	_
2-19	368-376	subjects	_
2-20	377-389	experiencing	_
2-21	390-392	DV	_
2-22	393-398	seems	_
2-23	399-401	to	_
2-24	402-408	mirror	_
2-25	409-412	the	_
2-26	413-425	distribution	_
2-27	426-428	of	_
2-28	429-432	GMV	_
2-29	433-442	reduction	_
2-30	443-445	in	_
2-31	446-452	mesial	_
2-32	453-461	temporal	_
2-33	462-466	lobe	_
2-34	467-475	epilepsy	_
2-35	476-477	(	_
2-36	478-482	MTLE	_
2-37	483-484	)	_
2-38	485-493	patients	_
2-39	494-497	but	_
2-40	498-502	vary	_
2-41	503-505	in	_
2-42	506-511	terms	_
2-43	512-514	of	_
2-44	515-518	the	_
2-45	519-530	hippocampus	_
2-46	531-532	.	_

Text=Another condition associated with hippocampal GMV reduction and DV alike disturbance in memory processing is schizophrenia (SCH).
3-1	533-540	Another	_
3-2	541-550	condition	_
3-3	551-561	associated	_
3-4	562-566	with	_
3-5	567-578	hippocampal	_
3-6	579-582	GMV	_
3-7	583-592	reduction	_
3-8	593-596	and	_
3-9	597-599	DV	_
3-10	600-605	alike	_
3-11	606-617	disturbance	_
3-12	618-620	in	_
3-13	621-627	memory	_
3-14	628-638	processing	_
3-15	639-641	is	_
3-16	642-655	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	656-657	(	_
3-18	658-661	SCH	_
3-19	662-663	)	_
3-20	664-665	.	_

Text=Here, we tested the hypothesis that hippocampal involvement in nonpathological DV resembles more closely the pattern of GMV decrease observed in MTLE compared with that occurring in SCH.
4-1	666-670	Here	_
4-2	671-672	,	_
4-3	673-675	we	_
4-4	676-682	tested	_
4-5	683-686	the	_
4-6	687-697	hypothesis	_
4-7	698-702	that	_
4-8	703-714	hippocampal	_
4-9	715-726	involvement	_
4-10	727-729	in	_
4-11	730-745	nonpathological	_
4-12	746-748	DV	_
4-13	749-758	resembles	_
4-14	759-763	more	_
4-15	764-771	closely	_
4-16	772-775	the	_
4-17	776-783	pattern	_
4-18	784-786	of	_
4-19	787-790	GMV	_
4-20	791-799	decrease	_
4-21	800-808	observed	_
4-22	809-811	in	_
4-23	812-816	MTLE	_
4-24	817-825	compared	_
4-25	826-830	with	_
4-26	831-835	that	_
4-27	836-845	occurring	_
4-28	846-848	in	_
4-29	849-852	SCH	_
4-30	853-854	.	_

Text=Methods Using automated segmentation of the MRI data we compared the medians of GMV within 12 specific hippocampal subfields in healthy individuals that do (DV+; N = 87) and do not report déjà vu experience (DV−; N = 26), and patients with MTLE (N = 47) and SCH (N = 29).
5-1	855-862	Methods	_
5-2	863-868	Using	_
5-3	869-878	automated	_
5-4	879-891	segmentation	_
5-5	892-894	of	_
5-6	895-898	the	_
5-7	899-902	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-8	903-907	data	_
5-9	908-910	we	_
5-10	911-919	compared	_
5-11	920-923	the	_
5-12	924-931	medians	_
5-13	932-934	of	_
5-14	935-938	GMV	_
5-15	939-945	within	_
5-16	946-948	12	_
5-17	949-957	specific	_
5-18	958-969	hippocampal	_
5-19	970-979	subfields	_
5-20	980-982	in	_
5-21	983-990	healthy	_
5-22	991-1002	individuals	_
5-23	1003-1007	that	_
5-24	1008-1010	do	_
5-25	1011-1012	(	_
5-26	1013-1016	DV+	_
5-27	1017-1018	;	_
5-28	1019-1020	N	_
5-29	1021-1022	=	_
5-30	1023-1025	87	_
5-31	1026-1027	)	_
5-32	1028-1031	and	_
5-33	1032-1034	do	_
5-34	1035-1038	not	_
5-35	1039-1045	report	_
5-36	1046-1050	déjà	_
5-37	1051-1053	vu	_
5-38	1054-1064	experience	_
5-39	1065-1066	(	_
5-40	1067-1070	DV−	_
5-41	1071-1072	;	_
5-42	1073-1074	N	_
5-43	1075-1076	=	_
5-44	1077-1079	26	_
5-45	1080-1081	)	_
5-46	1082-1083	,	_
5-47	1084-1087	and	_
5-48	1088-1096	patients	_
5-49	1097-1101	with	_
5-50	1102-1106	MTLE	_
5-51	1107-1108	(	_
5-52	1109-1110	N	_
5-53	1111-1112	=	_
5-54	1113-1115	47	_
5-55	1116-1117	)	_
5-56	1118-1121	and	_
5-57	1122-1125	SCH	_
5-58	1126-1127	(	_
5-59	1128-1129	N	_
5-60	1130-1131	=	_
5-61	1132-1134	29	_
5-62	1135-1136	)	_
5-63	1137-1138	.	_

Text=By Pearson correlation, we then evaluated the similarity of MTLE and SCH groups to DV+ group with respect to spatial distribution of GMV deviation from DV− group.
6-1	1139-1141	By	_
6-2	1142-1149	Pearson	_
6-3	1150-1161	correlation	_
6-4	1162-1163	,	_
6-5	1164-1166	we	_
6-6	1167-1171	then	_
6-7	1172-1181	evaluated	_
6-8	1182-1185	the	_
6-9	1186-1196	similarity	_
6-10	1197-1199	of	_
6-11	1200-1204	MTLE	_
6-12	1205-1208	and	_
6-13	1209-1212	SCH	_
6-14	1213-1219	groups	_
6-15	1220-1222	to	_
6-16	1223-1226	DV+	_
6-17	1227-1232	group	_
6-18	1233-1237	with	_
6-19	1238-1245	respect	_
6-20	1246-1248	to	_
6-21	1249-1256	spatial	_
6-22	1257-1269	distribution	_
6-23	1270-1272	of	_
6-24	1273-1276	GMV	_
6-25	1277-1286	deviation	_
6-26	1287-1291	from	_
6-27	1292-1295	DV−	_
6-28	1296-1301	group	_
6-29	1302-1303	.	_

Text=Results Significant GMV decrease was found in MTLE group in most of the subfields.
7-1	1304-1311	Results	_
7-2	1312-1323	Significant	_
7-3	1324-1327	GMV	_
7-4	1328-1336	decrease	_
7-5	1337-1340	was	_
7-6	1341-1346	found	_
7-7	1347-1349	in	_
7-8	1350-1354	MTLE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-9	1355-1360	group	_
7-10	1361-1363	in	_
7-11	1364-1368	most	_
7-12	1369-1371	of	_
7-13	1372-1375	the	_
7-14	1376-1385	subfields	_
7-15	1386-1387	.	_

Text=There were just trends in the hippocampal GMV decrease found in DV+ or SCH groups.
8-1	1388-1393	There	_
8-2	1394-1398	were	_
8-3	1399-1403	just	_
8-4	1404-1410	trends	_
8-5	1411-1413	in	_
8-6	1414-1417	the	_
8-7	1418-1429	hippocampal	_
8-8	1430-1433	GMV	_
8-9	1434-1442	decrease	_
8-10	1443-1448	found	_
8-11	1449-1451	in	_
8-12	1452-1455	DV+	_
8-13	1456-1458	or	_
8-14	1459-1462	SCH	_
8-15	1463-1469	groups	_
8-16	1470-1471	.	_

Text=Concerning the spatial distribution of GMV decrease, we revealed statistically significant correlation for the left hippocampus for SCH vs DV+.
9-1	1472-1482	Concerning	_
9-2	1483-1486	the	_
9-3	1487-1494	spatial	_
9-4	1495-1507	distribution	_
9-5	1508-1510	of	_
9-6	1511-1514	GMV	_
9-7	1515-1523	decrease	_
9-8	1524-1525	,	_
9-9	1526-1528	we	_
9-10	1529-1537	revealed	_
9-11	1538-1551	statistically	_
9-12	1552-1563	significant	_
9-13	1564-1575	correlation	_
9-14	1576-1579	for	_
9-15	1580-1583	the	_
9-16	1584-1588	left	_
9-17	1589-1600	hippocampus	_
9-18	1601-1604	for	_
9-19	1605-1608	SCH	_
9-20	1609-1611	vs	_
9-21	1612-1615	DV+	_
9-22	1616-1617	.	_

Text=Otherwise there was no statistically significant correlation.
10-1	1618-1627	Otherwise	_
10-2	1628-1633	there	_
10-3	1634-1637	was	_
10-4	1638-1640	no	_
10-5	1641-1654	statistically	_
10-6	1655-1666	significant	_
10-7	1667-1678	correlation	_
10-8	1679-1680	.	_

Text=Conclusions Our findings reveal structural features of hippocampal involvement in nonpathological DV, MTLE, and SCH.
11-1	1681-1692	Conclusions	_
11-2	1693-1696	Our	_
11-3	1697-1705	findings	_
11-4	1706-1712	reveal	_
11-5	1713-1723	structural	_
11-6	1724-1732	features	_
11-7	1733-1735	of	_
11-8	1736-1747	hippocampal	_
11-9	1748-1759	involvement	_
11-10	1760-1762	in	_
11-11	1763-1778	nonpathological	_
11-12	1779-1781	DV	_
11-13	1782-1783	,	_
11-14	1784-1788	MTLE	_
11-15	1789-1790	,	_
11-16	1791-1794	and	_
11-17	1795-1798	SCH	_
11-18	1799-1800	.	_

Text=Despite our expectations, the pattern of GMV reduction in the DV+ relative to the DV− group does not resemble the pattern observed in MTLE any more than that observed in SCH.
12-1	1801-1808	Despite	_
12-2	1809-1812	our	_
12-3	1813-1825	expectations	_
12-4	1826-1827	,	_
12-5	1828-1831	the	_
12-6	1832-1839	pattern	_
12-7	1840-1842	of	_
12-8	1843-1846	GMV	_
12-9	1847-1856	reduction	_
12-10	1857-1859	in	_
12-11	1860-1863	the	_
12-12	1864-1867	DV+	_
12-13	1868-1876	relative	_
12-14	1877-1879	to	_
12-15	1880-1883	the	_
12-16	1884-1887	DV−	_
12-17	1888-1893	group	_
12-18	1894-1898	does	_
12-19	1899-1902	not	_
12-20	1903-1911	resemble	_
12-21	1912-1915	the	_
12-22	1916-1923	pattern	_
12-23	1924-1932	observed	_
12-24	1933-1935	in	_
12-25	1936-1940	MTLE	_
12-26	1941-1944	any	_
12-27	1945-1949	more	_
12-28	1950-1954	than	_
12-29	1955-1959	that	_
12-30	1960-1968	observed	_
12-31	1969-1971	in	_
12-32	1972-1975	SCH	_
12-33	1976-1977	.	_

Text=The highly similar patterns of the three clinical groups rather suggest an increased vulnerability of certain hippocampal subfields; namely, Cornu Ammonis (CA) 4, CA3, dentate gyrus granular cell layer (GC‐DG), hippocampal–amygdaloid transition area (HATA) and subiculum.
13-1	1978-1981	The	_
13-2	1982-1988	highly	_
13-3	1989-1996	similar	_
13-4	1997-2005	patterns	_
13-5	2006-2008	of	_
13-6	2009-2012	the	_
13-7	2013-2018	three	_
13-8	2019-2027	clinical	_
13-9	2028-2034	groups	_
13-10	2035-2041	rather	_
13-11	2042-2049	suggest	_
13-12	2050-2052	an	_
13-13	2053-2062	increased	_
13-14	2063-2076	vulnerability	_
13-15	2077-2079	of	_
13-16	2080-2087	certain	_
13-17	2088-2099	hippocampal	_
13-18	2100-2109	subfields	_
13-19	2110-2111	;	_
13-20	2112-2118	namely	_
13-21	2119-2120	,	_
13-22	2121-2126	Cornu	_
13-23	2127-2134	Ammonis	_
13-24	2135-2136	(	_
13-25	2137-2139	CA	_
13-26	2140-2141	)	_
13-27	2142-2143	4	_
13-28	2144-2145	,	_
13-29	2146-2149	CA3	_
13-30	2150-2151	,	_
13-31	2152-2159	dentate	_
13-32	2160-2165	gyrus	_
13-33	2166-2174	granular	_
13-34	2175-2179	cell	_
13-35	2180-2185	layer	_
13-36	2186-2187	(	_
13-37	2188-2193	GC‐DG	_
13-38	2194-2195	)	_
13-39	2196-2197	,	_
13-40	2198-2220	hippocampal–amygdaloid	_
13-41	2221-2231	transition	_
13-42	2232-2236	area	_
13-43	2237-2238	(	_
13-44	2239-2243	HATA	_
13-45	2244-2245	)	_
13-46	2246-2249	and	_
13-47	2250-2259	subiculum	_
13-48	2260-2261	.	_

Text=METHODS Subjects Our sample comprised a total of 189 subjects participated in the study.
14-1	2262-2269	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
14-2	2270-2278	Subjects	_
14-3	2279-2282	Our	_
14-4	2283-2289	sample	_
14-5	2290-2299	comprised	_
14-6	2300-2301	a	_
14-7	2302-2307	total	_
14-8	2308-2310	of	_
14-9	2311-2314	189	_
14-10	2315-2323	subjects	_
14-11	2324-2336	participated	_
14-12	2337-2339	in	_
14-13	2340-2343	the	_
14-14	2344-2349	study	_
14-15	2350-2351	.	_

Text=The MTLE group consisted of a left‐sided (L‐MTLE; N = 27; 8M, 19F; median age = 40.2 years; range = 17.7 – 54.6 years) and right‐sided subgroup (R‐MTLE; N = 20; 6M, 14F; median age = 38.2 years; range = 24.8 – 61.1 years).
15-1	2352-2355	The	_
15-2	2356-2360	MTLE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-3	2361-2366	group	_
15-4	2367-2376	consisted	_
15-5	2377-2379	of	_
15-6	2380-2381	a	_
15-7	2382-2392	left‐sided	_
15-8	2393-2394	(	_
15-9	2395-2401	L‐MTLE	_
15-10	2402-2403	;	_
15-11	2404-2405	N	_
15-12	2406-2407	=	_
15-13	2408-2410	27	_
15-14	2411-2412	;	_
15-15	2413-2415	8M	_
15-16	2416-2417	,	_
15-17	2418-2421	19F	_
15-18	2422-2423	;	_
15-19	2424-2430	median	_
15-20	2431-2434	age	_
15-21	2435-2436	=	_
15-22	2437-2441	40.2	_
15-23	2442-2447	years	_
15-24	2448-2449	;	_
15-25	2450-2455	range	_
15-26	2456-2457	=	_
15-27	2458-2462	17.7	_
15-28	2463-2464	–	_
15-29	2465-2469	54.6	_
15-30	2470-2475	years	_
15-31	2476-2477	)	_
15-32	2478-2481	and	_
15-33	2482-2493	right‐sided	_
15-34	2494-2502	subgroup	_
15-35	2503-2504	(	_
15-36	2505-2511	R‐MTLE	_
15-37	2512-2513	;	_
15-38	2514-2515	N	_
15-39	2516-2517	=	_
15-40	2518-2520	20	_
15-41	2521-2522	;	_
15-42	2523-2525	6M	_
15-43	2526-2527	,	_
15-44	2528-2531	14F	_
15-45	2532-2533	;	_
15-46	2534-2540	median	_
15-47	2541-2544	age	_
15-48	2545-2546	=	_
15-49	2547-2551	38.2	_
15-50	2552-2557	years	_
15-51	2558-2559	;	_
15-52	2560-2565	range	_
15-53	2566-2567	=	_
15-54	2568-2572	24.8	_
15-55	2573-2574	–	_
15-56	2575-2579	61.1	_
15-57	2580-2585	years	_
15-58	2586-2587	)	_
15-59	2588-2589	.	_

Text=For the L‐MTLE subgroup, the median age at the time of disease onset was 3 years (range 1 – 35 years), the median disease duration was 32.5 years (range 6 – 54 years), and the median seizure frequency was 4 seizures per month (range 2 – 135 seizures).
16-1	2590-2593	For	_
16-2	2594-2597	the	_
16-3	2598-2604	L‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-4	2605-2613	subgroup	_
16-5	2614-2615	,	_
16-6	2616-2619	the	_
16-7	2620-2626	median	_
16-8	2627-2630	age	_
16-9	2631-2633	at	_
16-10	2634-2637	the	_
16-11	2638-2642	time	_
16-12	2643-2645	of	_
16-13	2646-2653	disease	_
16-14	2654-2659	onset	_
16-15	2660-2663	was	_
16-16	2664-2665	3	_
16-17	2666-2671	years	_
16-18	2672-2673	(	_
16-19	2674-2679	range	_
16-20	2680-2681	1	_
16-21	2682-2683	–	_
16-22	2684-2686	35	_
16-23	2687-2692	years	_
16-24	2693-2694	)	_
16-25	2695-2696	,	_
16-26	2697-2700	the	_
16-27	2701-2707	median	_
16-28	2708-2715	disease	_
16-29	2716-2724	duration	_
16-30	2725-2728	was	_
16-31	2729-2733	32.5	_
16-32	2734-2739	years	_
16-33	2740-2741	(	_
16-34	2742-2747	range	_
16-35	2748-2749	6	_
16-36	2750-2751	–	_
16-37	2752-2754	54	_
16-38	2755-2760	years	_
16-39	2761-2762	)	_
16-40	2763-2764	,	_
16-41	2765-2768	and	_
16-42	2769-2772	the	_
16-43	2773-2779	median	_
16-44	2780-2787	seizure	_
16-45	2788-2797	frequency	_
16-46	2798-2801	was	_
16-47	2802-2803	4	_
16-48	2804-2812	seizures	_
16-49	2813-2816	per	_
16-50	2817-2822	month	_
16-51	2823-2824	(	_
16-52	2825-2830	range	_
16-53	2831-2832	2	_
16-54	2833-2834	–	_
16-55	2835-2838	135	_
16-56	2839-2847	seizures	_
16-57	2848-2849	)	_
16-58	2850-2851	.	_

Text=For the R‐MTLE subgroup, the median age at the time of the disease onset was 5.5 years (range 8 months – 40 years), the median disease duration was 29.5 years (range 8 – 55 years), and the median seizure frequency was 4.75 seizures per month (1 – 13).
17-1	2852-2855	For	_
17-2	2856-2859	the	_
17-3	2860-2866	R‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
17-4	2867-2875	subgroup	_
17-5	2876-2877	,	_
17-6	2878-2881	the	_
17-7	2882-2888	median	_
17-8	2889-2892	age	_
17-9	2893-2895	at	_
17-10	2896-2899	the	_
17-11	2900-2904	time	_
17-12	2905-2907	of	_
17-13	2908-2911	the	_
17-14	2912-2919	disease	_
17-15	2920-2925	onset	_
17-16	2926-2929	was	_
17-17	2930-2933	5.5	_
17-18	2934-2939	years	_
17-19	2940-2941	(	_
17-20	2942-2947	range	_
17-21	2948-2949	8	_
17-22	2950-2956	months	_
17-23	2957-2958	–	_
17-24	2959-2961	40	_
17-25	2962-2967	years	_
17-26	2968-2969	)	_
17-27	2970-2971	,	_
17-28	2972-2975	the	_
17-29	2976-2982	median	_
17-30	2983-2990	disease	_
17-31	2991-2999	duration	_
17-32	3000-3003	was	_
17-33	3004-3008	29.5	_
17-34	3009-3014	years	_
17-35	3015-3016	(	_
17-36	3017-3022	range	_
17-37	3023-3024	8	_
17-38	3025-3026	–	_
17-39	3027-3029	55	_
17-40	3030-3035	years	_
17-41	3036-3037	)	_
17-42	3038-3039	,	_
17-43	3040-3043	and	_
17-44	3044-3047	the	_
17-45	3048-3054	median	_
17-46	3055-3062	seizure	_
17-47	3063-3072	frequency	_
17-48	3073-3076	was	_
17-49	3077-3081	4.75	_
17-50	3082-3090	seizures	_
17-51	3091-3094	per	_
17-52	3095-3100	month	_
17-53	3101-3102	(	_
17-54	3103-3104	1	_
17-55	3105-3106	–	_
17-56	3107-3109	13	_
17-57	3110-3111	)	_
17-58	3112-3113	.	_

Text=At the time of testing, the subgroups did not differ significantly in age (p = .97, T–test), gender (p = .48; T–test), disease duration (p = .60, T–test) or seizure frequency (p = .40, T–test).
18-1	3114-3116	At	_
18-2	3117-3120	the	_
18-3	3121-3125	time	_
18-4	3126-3128	of	_
18-5	3129-3136	testing	_
18-6	3137-3138	,	_
18-7	3139-3142	the	_
18-8	3143-3152	subgroups	_
18-9	3153-3156	did	_
18-10	3157-3160	not	_
18-11	3161-3167	differ	_
18-12	3168-3181	significantly	_
18-13	3182-3184	in	_
18-14	3185-3188	age	_
18-15	3189-3190	(	_
18-16	3191-3192	p	_
18-17	3193-3194	=	_
18-18	3195-3198	.97	_
18-19	3199-3200	,	_
18-20	3201-3207	T–test	_
18-21	3208-3209	)	_
18-22	3210-3211	,	_
18-23	3212-3218	gender	_
18-24	3219-3220	(	_
18-25	3221-3222	p	_
18-26	3223-3224	=	_
18-27	3225-3228	.48	_
18-28	3229-3230	;	_
18-29	3231-3237	T–test	_
18-30	3238-3239	)	_
18-31	3240-3241	,	_
18-32	3242-3249	disease	_
18-33	3250-3258	duration	_
18-34	3259-3260	(	_
18-35	3261-3262	p	_
18-36	3263-3264	=	_
18-37	3265-3268	.60	_
18-38	3269-3270	,	_
18-39	3271-3277	T–test	_
18-40	3278-3279	)	_
18-41	3280-3282	or	_
18-42	3283-3290	seizure	_
18-43	3291-3300	frequency	_
18-44	3301-3302	(	_
18-45	3303-3304	p	_
18-46	3305-3306	=	_
18-47	3307-3310	.40	_
18-48	3311-3312	,	_
18-49	3313-3319	T–test	_
18-50	3320-3321	)	_
18-51	3322-3323	.	_

Text=There was no significant variance between the subgroups in their positive history of febrile convulsions (seven in L‐MTLE and six in R‐MTLE; p = .74, T–test).
19-1	3324-3329	There	_
19-2	3330-3333	was	_
19-3	3334-3336	no	_
19-4	3337-3348	significant	_
19-5	3349-3357	variance	_
19-6	3358-3365	between	_
19-7	3366-3369	the	_
19-8	3370-3379	subgroups	_
19-9	3380-3382	in	_
19-10	3383-3388	their	_
19-11	3389-3397	positive	_
19-12	3398-3405	history	_
19-13	3406-3408	of	_
19-14	3409-3416	febrile	_
19-15	3417-3428	convulsions	_
19-16	3429-3430	(	_
19-17	3431-3436	seven	_
19-18	3437-3439	in	_
19-19	3440-3446	L‐MTLE	_
19-20	3447-3450	and	_
19-21	3451-3454	six	_
19-22	3455-3457	in	_
19-23	3458-3464	R‐MTLE	_
19-24	3465-3466	;	_
19-25	3467-3468	p	_
19-26	3469-3470	=	_
19-27	3471-3474	.74	_
19-28	3475-3476	,	_
19-29	3477-3483	T–test	_
19-30	3484-3485	)	_
19-31	3486-3487	.	_

Text=Majority of the subjects had a history of complex partial seizures.
20-1	3488-3496	Majority	_
20-2	3497-3499	of	_
20-3	3500-3503	the	_
20-4	3504-3512	subjects	_
20-5	3513-3516	had	_
20-6	3517-3518	a	_
20-7	3519-3526	history	_
20-8	3527-3529	of	_
20-9	3530-3537	complex	_
20-10	3538-3545	partial	_
20-11	3546-3554	seizures	_
20-12	3555-3556	.	_

Text=Ten patients in the L‐MTLE subgroup and eight patients in the R‐MTLE subgroup also presented secondary generalized seizures.
21-1	3557-3560	Ten	_
21-2	3561-3569	patients	_
21-3	3570-3572	in	_
21-4	3573-3576	the	_
21-5	3577-3583	L‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-6	3584-3592	subgroup	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-7	3593-3596	and	_
21-8	3597-3602	eight	_
21-9	3603-3611	patients	_
21-10	3612-3614	in	_
21-11	3615-3618	the	_
21-12	3619-3625	R‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
21-13	3626-3634	subgroup	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
21-14	3635-3639	also	_
21-15	3640-3649	presented	_
21-16	3650-3659	secondary	_
21-17	3660-3671	generalized	_
21-18	3672-3680	seizures	_
21-19	3681-3682	.	_

Text=One patient with L‐MTLE and one with R‐MTLE had simple partial seizures.
22-1	3683-3686	One	_
22-2	3687-3694	patient	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
22-3	3695-3699	with	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
22-4	3700-3706	L‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-5	3707-3710	and	_
22-6	3711-3714	one	_
22-7	3715-3719	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
22-8	3720-3726	R‐MTLE	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
22-9	3727-3730	had	_
22-10	3731-3737	simple	_
22-11	3738-3745	partial	_
22-12	3746-3754	seizures	_
22-13	3755-3756	.	_

Text=DV in the context of aura was reported solely by one patient.
23-1	3757-3759	DV	_
23-2	3760-3762	in	_
23-3	3763-3766	the	_
23-4	3767-3774	context	_
23-5	3775-3777	of	_
23-6	3778-3782	aura	_
23-7	3783-3786	was	_
23-8	3787-3795	reported	_
23-9	3796-3802	solely	_
23-10	3803-3805	by	_
23-11	3806-3809	one	_
23-12	3810-3817	patient	_
23-13	3818-3819	.	_

Text=The only statistically significant divergence between the subgroups was in the number of prescribed antiepileptic drugs (number of types): a mean of 2.3 medications for the L‐MTLE subgroup, and a mean of 1.8 medications for R‐MTLE subgroup (p = .03, T‐test).
24-1	3820-3823	The	_
24-2	3824-3828	only	_
24-3	3829-3842	statistically	_
24-4	3843-3854	significant	_
24-5	3855-3865	divergence	_
24-6	3866-3873	between	_
24-7	3874-3877	the	_
24-8	3878-3887	subgroups	_
24-9	3888-3891	was	_
24-10	3892-3894	in	_
24-11	3895-3898	the	_
24-12	3899-3905	number	_
24-13	3906-3908	of	_
24-14	3909-3919	prescribed	_
24-15	3920-3933	antiepileptic	_
24-16	3934-3939	drugs	_
24-17	3940-3941	(	_
24-18	3942-3948	number	_
24-19	3949-3951	of	_
24-20	3952-3957	types	_
24-21	3958-3959	)	_
24-22	3960-3961	:	_
24-23	3962-3963	a	_
24-24	3964-3968	mean	_
24-25	3969-3971	of	_
24-26	3972-3975	2.3	_
24-27	3976-3987	medications	_
24-28	3988-3991	for	_
24-29	3992-3995	the	_
24-30	3996-4002	L‐MTLE	_
24-31	4003-4011	subgroup	_
24-32	4012-4013	,	_
24-33	4014-4017	and	_
24-34	4018-4019	a	_
24-35	4020-4024	mean	_
24-36	4025-4027	of	_
24-37	4028-4031	1.8	_
24-38	4032-4043	medications	_
24-39	4044-4047	for	_
24-40	4048-4054	R‐MTLE	_
24-41	4055-4063	subgroup	_
24-42	4064-4065	(	_
24-43	4066-4067	p	_
24-44	4068-4069	=	_
24-45	4070-4073	.03	_
24-46	4074-4075	,	_
24-47	4076-4082	T‐test	_
24-48	4083-4084	)	_
24-49	4085-4086	.	_

Text=The diagnosis of unilateral MTLE was based on a consonance of history data, ictal and interictal EEG findings (long‐term semi‐invasive video‐EEG monitoring with sphenoidal electrodes), ictal semiology, neuropsychology, neuroimaging findings, and fulfillment of the diagnostic criteria for MTLE according to the International League Against Epilepsy (ILAE) criteria (Commission on Classification and Terminology of ILAE, 1989).
25-1	4087-4090	The	_
25-2	4091-4100	diagnosis	_
25-3	4101-4103	of	_
25-4	4104-4114	unilateral	http://maven.renci.org/NeuroBridge/neurobridge#LateralLumbarSpineXRay
25-5	4115-4119	MTLE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-6	4120-4123	was	_
25-7	4124-4129	based	_
25-8	4130-4132	on	_
25-9	4133-4134	a	_
25-10	4135-4145	consonance	_
25-11	4146-4148	of	_
25-12	4149-4156	history	_
25-13	4157-4161	data	_
25-14	4162-4163	,	_
25-15	4164-4169	ictal	_
25-16	4170-4173	and	_
25-17	4174-4184	interictal	_
25-18	4185-4188	EEG	_
25-19	4189-4197	findings	_
25-20	4198-4199	(	_
25-21	4200-4209	long‐term	_
25-22	4210-4223	semi‐invasive	_
25-23	4224-4233	video‐EEG	_
25-24	4234-4244	monitoring	_
25-25	4245-4249	with	_
25-26	4250-4260	sphenoidal	_
25-27	4261-4271	electrodes	_
25-28	4272-4273	)	_
25-29	4274-4275	,	_
25-30	4276-4281	ictal	_
25-31	4282-4291	semiology	_
25-32	4292-4293	,	_
25-33	4294-4309	neuropsychology	_
25-34	4310-4311	,	_
25-35	4312-4324	neuroimaging	_
25-36	4325-4333	findings	_
25-37	4334-4335	,	_
25-38	4336-4339	and	_
25-39	4340-4351	fulfillment	_
25-40	4352-4354	of	_
25-41	4355-4358	the	_
25-42	4359-4369	diagnostic	_
25-43	4370-4378	criteria	_
25-44	4379-4382	for	_
25-45	4383-4387	MTLE	_
25-46	4388-4397	according	_
25-47	4398-4400	to	_
25-48	4401-4404	the	_
25-49	4405-4418	International	_
25-50	4419-4425	League	_
25-51	4426-4433	Against	_
25-52	4434-4442	Epilepsy	_
25-53	4443-4444	(	_
25-54	4445-4449	ILAE	_
25-55	4450-4451	)	_
25-56	4452-4460	criteria	_
25-57	4461-4462	(	_
25-58	4463-4473	Commission	_
25-59	4474-4476	on	_
25-60	4477-4491	Classification	_
25-61	4492-4495	and	_
25-62	4496-4507	Terminology	_
25-63	4508-4510	of	_
25-64	4511-4515	ILAE	_
25-65	4516-4517	,	_
25-66	4518-4522	1989	_
25-67	4523-4524	)	_
25-68	4525-4526	.	_

Text=As another inclusion criteria was set also hippocampal sclerosis, which is a substrate characterizing classical TLE (Hogan, 2001).
26-1	4527-4529	As	_
26-2	4530-4537	another	_
26-3	4538-4547	inclusion	_
26-4	4548-4556	criteria	_
26-5	4557-4560	was	_
26-6	4561-4564	set	_
26-7	4565-4569	also	_
26-8	4570-4581	hippocampal	_
26-9	4582-4591	sclerosis	_
26-10	4592-4593	,	_
26-11	4594-4599	which	_
26-12	4600-4602	is	_
26-13	4603-4604	a	_
26-14	4605-4614	substrate	_
26-15	4615-4629	characterizing	_
26-16	4630-4639	classical	_
26-17	4640-4643	TLE	_
26-18	4644-4645	(	_
26-19	4646-4651	Hogan	_
26-20	4652-4653	,	_
26-21	4654-4658	2001	_
26-22	4659-4660	)	_
26-23	4661-4662	.	_

Text=Unilateral hippocampal sclerosis MRI evidence concordant with the EEG lateralization of the epileptogenic zone was found in all subjects.
27-1	4663-4673	Unilateral	_
27-2	4674-4685	hippocampal	_
27-3	4686-4695	sclerosis	_
27-4	4696-4699	MRI	_
27-5	4700-4708	evidence	_
27-6	4709-4719	concordant	_
27-7	4720-4724	with	_
27-8	4725-4728	the	_
27-9	4729-4732	EEG	_
27-10	4733-4747	lateralization	_
27-11	4748-4750	of	_
27-12	4751-4754	the	_
27-13	4755-4768	epileptogenic	_
27-14	4769-4773	zone	_
27-15	4774-4777	was	_
27-16	4778-4783	found	_
27-17	4784-4786	in	_
27-18	4787-4790	all	_
27-19	4791-4799	subjects	_
27-20	4800-4801	.	_

Text=None of the subjects revealed any other structural brain lesions on MRI scans, and none had undergone previous intracranial surgery.
28-1	4802-4806	None	_
28-2	4807-4809	of	_
28-3	4810-4813	the	_
28-4	4814-4822	subjects	_
28-5	4823-4831	revealed	_
28-6	4832-4835	any	_
28-7	4836-4841	other	_
28-8	4842-4852	structural	_
28-9	4853-4858	brain	_
28-10	4859-4866	lesions	_
28-11	4867-4869	on	_
28-12	4870-4873	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-13	4874-4879	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-14	4880-4881	,	_
28-15	4882-4885	and	_
28-16	4886-4890	none	_
28-17	4891-4894	had	_
28-18	4895-4904	undergone	_
28-19	4905-4913	previous	_
28-20	4914-4926	intracranial	_
28-21	4927-4934	surgery	_
28-22	4935-4936	.	_

Text=All subjects had been seizure free for 24 hr prior to the MRI investigation.
29-1	4937-4940	All	_
29-2	4941-4949	subjects	_
29-3	4950-4953	had	_
29-4	4954-4958	been	_
29-5	4959-4966	seizure	_
29-6	4967-4971	free	_
29-7	4972-4975	for	_
29-8	4976-4978	24	_
29-9	4979-4981	hr	_
29-10	4982-4987	prior	_
29-11	4988-4990	to	_
29-12	4991-4994	the	_
29-13	4995-4998	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-14	4999-5012	investigation	_
29-15	5013-5014	.	_

Text=The SCH group comprised of 29 subjects (23M, 6F; median age = 33 years; range = 19.3 – 45.1 years) with a median disease duration of 4.5 years (range = 1 ‐ 288 months).
30-1	5015-5018	The	_
30-2	5019-5022	SCH	http://maven.renci.org/NeuroBridge/neurobridge#Schizotypy
30-3	5023-5028	group	_
30-4	5029-5038	comprised	_
30-5	5039-5041	of	_
30-6	5042-5044	29	_
30-7	5045-5053	subjects	_
30-8	5054-5055	(	_
30-9	5056-5059	23M	_
30-10	5060-5061	,	_
30-11	5062-5064	6F	_
30-12	5065-5066	;	_
30-13	5067-5073	median	_
30-14	5074-5077	age	_
30-15	5078-5079	=	_
30-16	5080-5082	33	_
30-17	5083-5088	years	_
30-18	5089-5090	;	_
30-19	5091-5096	range	_
30-20	5097-5098	=	_
30-21	5099-5103	19.3	_
30-22	5104-5105	–	_
30-23	5106-5110	45.1	_
30-24	5111-5116	years	_
30-25	5117-5118	)	_
30-26	5119-5123	with	_
30-27	5124-5125	a	_
30-28	5126-5132	median	_
30-29	5133-5140	disease	_
30-30	5141-5149	duration	_
30-31	5150-5152	of	_
30-32	5153-5156	4.5	_
30-33	5157-5162	years	_
30-34	5163-5164	(	_
30-35	5165-5170	range	_
30-36	5171-5172	=	_
30-37	5173-5174	1	_
30-38	5175-5176	‐	_
30-39	5177-5180	288	_
30-40	5181-5187	months	_
30-41	5188-5189	)	_
30-42	5190-5191	.	_

Text=The symptom severity in these patients was assessed with Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987).
31-1	5192-5195	The	_
31-2	5196-5203	symptom	_
31-3	5204-5212	severity	_
31-4	5213-5215	in	_
31-5	5216-5221	these	_
31-6	5222-5230	patients	_
31-7	5231-5234	was	_
31-8	5235-5243	assessed	_
31-9	5244-5248	with	_
31-10	5249-5257	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-11	5258-5261	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-12	5262-5270	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-13	5271-5279	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-14	5280-5285	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-15	5286-5287	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-16	5288-5293	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-17	5294-5295	;	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-18	5296-5299	Kay	_
31-19	5300-5301	,	_
31-20	5302-5310	Fiszbein	_
31-21	5311-5312	,	_
31-22	5313-5314	&	_
31-23	5315-5320	Opler	_
31-24	5321-5322	,	_
31-25	5323-5327	1987	_
31-26	5328-5329	)	_
31-27	5330-5331	.	_

Text=Patients scored a median of 14 points (range = 7 – 20 points) on the positive scale, a median score of 21 points (range = 10 – 29 points) on the negative scale, and a median of 38 points (range = 21 – 53 points) on the general psychopathology scale.
32-1	5332-5340	Patients	_
32-2	5341-5347	scored	_
32-3	5348-5349	a	_
32-4	5350-5356	median	_
32-5	5357-5359	of	_
32-6	5360-5362	14	_
32-7	5363-5369	points	_
32-8	5370-5371	(	_
32-9	5372-5377	range	_
32-10	5378-5379	=	_
32-11	5380-5381	7	_
32-12	5382-5383	–	_
32-13	5384-5386	20	_
32-14	5387-5393	points	_
32-15	5394-5395	)	_
32-16	5396-5398	on	_
32-17	5399-5402	the	_
32-18	5403-5411	positive	_
32-19	5412-5417	scale	_
32-20	5418-5419	,	_
32-21	5420-5421	a	_
32-22	5422-5428	median	_
32-23	5429-5434	score	_
32-24	5435-5437	of	_
32-25	5438-5440	21	_
32-26	5441-5447	points	_
32-27	5448-5449	(	_
32-28	5450-5455	range	_
32-29	5456-5457	=	_
32-30	5458-5460	10	_
32-31	5461-5462	–	_
32-32	5463-5465	29	_
32-33	5466-5472	points	_
32-34	5473-5474	)	_
32-35	5475-5477	on	_
32-36	5478-5481	the	_
32-37	5482-5490	negative	_
32-38	5491-5496	scale	_
32-39	5497-5498	,	_
32-40	5499-5502	and	_
32-41	5503-5504	a	_
32-42	5505-5511	median	_
32-43	5512-5514	of	_
32-44	5515-5517	38	_
32-45	5518-5524	points	_
32-46	5525-5526	(	_
32-47	5527-5532	range	_
32-48	5533-5534	=	_
32-49	5535-5537	21	_
32-50	5538-5539	–	_
32-51	5540-5542	53	_
32-52	5543-5549	points	_
32-53	5550-5551	)	_
32-54	5552-5554	on	_
32-55	5555-5558	the	_
32-56	5559-5566	general	_
32-57	5567-5582	psychopathology	_
32-58	5583-5588	scale	_
32-59	5589-5590	.	_

Text=The median of experienced episodes was 2 (range = 1 ‐ 8 episodes) during the course of the disease, and all subjects were on stable antipsychotic medication with median of 1 (range = 1‐2 drugs, all atypical antipsychotics).
33-1	5591-5594	The	_
33-2	5595-5601	median	_
33-3	5602-5604	of	_
33-4	5605-5616	experienced	_
33-5	5617-5625	episodes	_
33-6	5626-5629	was	_
33-7	5630-5631	2	_
33-8	5632-5633	(	_
33-9	5634-5639	range	_
33-10	5640-5641	=	_
33-11	5642-5643	1	_
33-12	5644-5645	‐	_
33-13	5646-5647	8	_
33-14	5648-5656	episodes	_
33-15	5657-5658	)	_
33-16	5659-5665	during	_
33-17	5666-5669	the	_
33-18	5670-5676	course	_
33-19	5677-5679	of	_
33-20	5680-5683	the	_
33-21	5684-5691	disease	_
33-22	5692-5693	,	_
33-23	5694-5697	and	_
33-24	5698-5701	all	_
33-25	5702-5710	subjects	_
33-26	5711-5715	were	_
33-27	5716-5718	on	_
33-28	5719-5725	stable	_
33-29	5726-5739	antipsychotic	_
33-30	5740-5750	medication	_
33-31	5751-5755	with	_
33-32	5756-5762	median	_
33-33	5763-5765	of	_
33-34	5766-5767	1	_
33-35	5768-5769	(	_
33-36	5770-5775	range	_
33-37	5776-5777	=	_
33-38	5778-5781	1‐2	_
33-39	5782-5787	drugs	_
33-40	5788-5789	,	_
33-41	5790-5793	all	_
33-42	5794-5802	atypical	_
33-43	5803-5817	antipsychotics	_
33-44	5818-5819	)	_
33-45	5820-5821	.	_

Text=None of the subjects reported history of epilepsy or signs of hippocampal sclerosis on MRI.
34-1	5822-5826	None	_
34-2	5827-5829	of	_
34-3	5830-5833	the	_
34-4	5834-5842	subjects	_
34-5	5843-5851	reported	_
34-6	5852-5859	history	_
34-7	5860-5862	of	_
34-8	5863-5871	epilepsy	_
34-9	5872-5874	or	_
34-10	5875-5880	signs	_
34-11	5881-5883	of	_
34-12	5884-5895	hippocampal	_
34-13	5896-5905	sclerosis	_
34-14	5906-5908	on	_
34-15	5909-5912	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-16	5913-5914	.	_

Text=The DV+ group comprised of 87 healthy volunteers (45M, 42F; median age = 24.1 years; range = 19.1 – 46.2 years) with no personal or family history of epilepsy or schizophrenia.
35-1	5915-5918	The	_
35-2	5919-5922	DV+	_
35-3	5923-5928	group	_
35-4	5929-5938	comprised	_
35-5	5939-5941	of	_
35-6	5942-5944	87	_
35-7	5945-5952	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-8	5953-5963	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-9	5964-5965	(	_
35-10	5966-5969	45M	_
35-11	5970-5971	,	_
35-12	5972-5975	42F	_
35-13	5976-5977	;	_
35-14	5978-5984	median	_
35-15	5985-5988	age	_
35-16	5989-5990	=	_
35-17	5991-5995	24.1	_
35-18	5996-6001	years	_
35-19	6002-6003	;	_
35-20	6004-6009	range	_
35-21	6010-6011	=	_
35-22	6012-6016	19.1	_
35-23	6017-6018	–	_
35-24	6019-6023	46.2	_
35-25	6024-6029	years	_
35-26	6030-6031	)	_
35-27	6032-6036	with	_
35-28	6037-6039	no	_
35-29	6040-6048	personal	_
35-30	6049-6051	or	_
35-31	6052-6058	family	_
35-32	6059-6066	history	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
35-33	6067-6069	of	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
35-34	6070-6078	epilepsy	_
35-35	6079-6081	or	_
35-36	6082-6095	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-37	6096-6097	.	_

Text=All subjects completed the Inventory for Déjà vu Experiences Assessment (IDEA) —a questionnaire used widely in previous DV research (Sno, Schalken, de Jonghe, & Koeter, 1994) —and answered “ yes ” to the question A1: ” Have you ever had the feeling of having experienced a sensation or situation before in exactly the same way when in fact you are experiencing it for the first time? ”.
36-1	6098-6101	All	_
36-2	6102-6110	subjects	_
36-3	6111-6120	completed	_
36-4	6121-6124	the	_
36-5	6125-6134	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-6	6135-6138	for	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-7	6139-6143	Déjà	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-8	6144-6146	vu	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-9	6147-6158	Experiences	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-10	6159-6169	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-11	6170-6171	(	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-12	6172-6176	IDEA	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-13	6177-6178	)	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
36-14	6179-6181	—a	_
36-15	6182-6195	questionnaire	_
36-16	6196-6200	used	_
36-17	6201-6207	widely	_
36-18	6208-6210	in	_
36-19	6211-6219	previous	_
36-20	6220-6222	DV	_
36-21	6223-6231	research	_
36-22	6232-6233	(	_
36-23	6234-6237	Sno	_
36-24	6238-6239	,	_
36-25	6240-6248	Schalken	_
36-26	6249-6250	,	_
36-27	6251-6253	de	_
36-28	6254-6260	Jonghe	_
36-29	6261-6262	,	_
36-30	6263-6264	&	_
36-31	6265-6271	Koeter	_
36-32	6272-6273	,	_
36-33	6274-6278	1994	_
36-34	6279-6280	)	_
36-35	6281-6285	—and	_
36-36	6286-6294	answered	_
36-37	6295-6296	“	_
36-38	6297-6300	yes	_
36-39	6301-6302	”	_
36-40	6303-6305	to	_
36-41	6306-6309	the	_
36-42	6310-6318	question	_
36-43	6319-6321	A1	_
36-44	6322-6323	:	_
36-45	6324-6325	”	_
36-46	6326-6330	Have	_
36-47	6331-6334	you	_
36-48	6335-6339	ever	_
36-49	6340-6343	had	_
36-50	6344-6347	the	_
36-51	6348-6355	feeling	_
36-52	6356-6358	of	_
36-53	6359-6365	having	_
36-54	6366-6377	experienced	_
36-55	6378-6379	a	_
36-56	6380-6389	sensation	_
36-57	6390-6392	or	_
36-58	6393-6402	situation	_
36-59	6403-6409	before	_
36-60	6410-6412	in	_
36-61	6413-6420	exactly	_
36-62	6421-6424	the	_
36-63	6425-6429	same	_
36-64	6430-6433	way	_
36-65	6434-6438	when	_
36-66	6439-6441	in	_
36-67	6442-6446	fact	_
36-68	6447-6450	you	_
36-69	6451-6454	are	_
36-70	6455-6467	experiencing	_
36-71	6468-6470	it	_
36-72	6471-6474	for	_
36-73	6475-6478	the	_
36-74	6479-6484	first	_
36-75	6485-6489	time	_
36-76	6490-6491	?	_
36-77	6492-6493	”	_
36-78	6494-6495	.	_

Text=The DV− group included 26 healthy volunteers (14M, 12F; median age = 24.2 years; range = 20.3 – 49.5 years) with no personal or family history of epilepsy or schizophrenia.
37-1	6496-6499	The	_
37-2	6500-6503	DV−	_
37-3	6504-6509	group	_
37-4	6510-6518	included	_
37-5	6519-6521	26	_
37-6	6522-6529	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
37-7	6530-6540	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
37-8	6541-6542	(	_
37-9	6543-6546	14M	_
37-10	6547-6548	,	_
37-11	6549-6552	12F	_
37-12	6553-6554	;	_
37-13	6555-6561	median	_
37-14	6562-6565	age	_
37-15	6566-6567	=	_
37-16	6568-6572	24.2	_
37-17	6573-6578	years	_
37-18	6579-6580	;	_
37-19	6581-6586	range	_
37-20	6587-6588	=	_
37-21	6589-6593	20.3	_
37-22	6594-6595	–	_
37-23	6596-6600	49.5	_
37-24	6601-6606	years	_
37-25	6607-6608	)	_
37-26	6609-6613	with	_
37-27	6614-6616	no	_
37-28	6617-6625	personal	_
37-29	6626-6628	or	_
37-30	6629-6635	family	_
37-31	6636-6643	history	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
37-32	6644-6646	of	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
37-33	6647-6655	epilepsy	_
37-34	6656-6658	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
37-35	6659-6672	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
37-36	6673-6674	.	_

Text=These individuals answered “ never ” to question A1 of the IDEA questionnaire.
38-1	6675-6680	These	_
38-2	6681-6692	individuals	_
38-3	6693-6701	answered	_
38-4	6702-6703	“	_
38-5	6704-6709	never	_
38-6	6710-6711	”	_
38-7	6712-6714	to	_
38-8	6715-6723	question	_
38-9	6724-6726	A1	_
38-10	6727-6729	of	_
38-11	6730-6733	the	_
38-12	6734-6738	IDEA	_
38-13	6739-6752	questionnaire	_
38-14	6753-6754	.	_

Text=Group factor testing reached statistical significance in the case of age (Kruskal‐Wallis test H [4,189] = 59.6, p <.001) and gender (Pearson Chi‐square test, chi‐square = 17.9, p = .001).
39-1	6755-6760	Group	_
39-2	6761-6767	factor	_
39-3	6768-6775	testing	_
39-4	6776-6783	reached	_
39-5	6784-6795	statistical	_
39-6	6796-6808	significance	_
39-7	6809-6811	in	_
39-8	6812-6815	the	_
39-9	6816-6820	case	_
39-10	6821-6823	of	_
39-11	6824-6827	age	_
39-12	6828-6829	(	_
39-13	6830-6844	Kruskal‐Wallis	_
39-14	6845-6849	test	_
39-15	6850-6851	H	_
39-16	6852-6853	[	_
39-17	6854-6859	4,189	_
39-18	6860-6861	]	_
39-19	6862-6863	=	_
39-20	6864-6868	59.6	_
39-21	6869-6870	,	_
39-22	6871-6872	p	_
39-23	6873-6874	<	_
39-24	6875-6879	.001	_
39-25	6880-6881	)	_
39-26	6882-6885	and	_
39-27	6886-6892	gender	_
39-28	6893-6894	(	_
39-29	6895-6902	Pearson	_
39-30	6903-6913	Chi‐square	_
39-31	6914-6918	test	_
39-32	6919-6920	,	_
39-33	6921-6931	chi‐square	_
39-34	6932-6933	=	_
39-35	6934-6938	17.9	_
39-36	6939-6940	,	_
39-37	6941-6942	p	_
39-38	6943-6944	=	_
39-39	6945-6949	.001	_
39-40	6950-6951	)	_
39-41	6952-6953	.	_

Text=Written informed consent was obtained from each participant after all the procedures were explained in full.
40-1	6954-6961	Written	_
40-2	6962-6970	informed	_
40-3	6971-6978	consent	_
40-4	6979-6982	was	_
40-5	6983-6991	obtained	_
40-6	6992-6996	from	_
40-7	6997-7001	each	_
40-8	7002-7013	participant	_
40-9	7014-7019	after	_
40-10	7020-7023	all	_
40-11	7024-7027	the	_
40-12	7028-7038	procedures	_
40-13	7039-7043	were	_
40-14	7044-7053	explained	_
40-15	7054-7056	in	_
40-16	7057-7061	full	_
40-17	7062-7063	.	_

Text=The study received the approval of the local ethics committee.
41-1	7064-7067	The	_
41-2	7068-7073	study	_
41-3	7074-7082	received	_
41-4	7083-7086	the	_
41-5	7087-7095	approval	_
41-6	7096-7098	of	_
41-7	7099-7102	the	_
41-8	7103-7108	local	_
41-9	7109-7115	ethics	_
41-10	7116-7125	committee	_
41-11	7126-7127	.	_

Text=MRI data acquisition We acquired a T1 MPRAGE high resolution MRI for each subject with a Siemens Symphony 1.5T MR scanner (160 sagittal slices; matrix size 256 × 256, resampled to 512 × 512; TR = 1,700 ms; TE = 3.96 ms; FOV = 246 mm; FA = 15°; slice thickness = 1.17 mm; native in plane resolution = 0.96 mm).
42-1	7128-7131	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-2	7132-7136	data	_
42-3	7137-7148	acquisition	_
42-4	7149-7151	We	_
42-5	7152-7160	acquired	_
42-6	7161-7162	a	_
42-7	7163-7165	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-8	7166-7172	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-9	7173-7177	high	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-10	7178-7188	resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-11	7189-7192	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-12	7193-7196	for	_
42-13	7197-7201	each	_
42-14	7202-7209	subject	_
42-15	7210-7214	with	_
42-16	7215-7216	a	_
42-17	7217-7224	Siemens	_
42-18	7225-7233	Symphony	_
42-19	7234-7238	1.5T	_
42-20	7239-7241	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-21	7242-7249	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-22	7250-7251	(	_
42-23	7252-7255	160	_
42-24	7256-7264	sagittal	_
42-25	7265-7271	slices	_
42-26	7272-7273	;	_
42-27	7274-7280	matrix	_
42-28	7281-7285	size	_
42-29	7286-7289	256	_
42-30	7290-7291	×	_
42-31	7292-7295	256	_
42-32	7296-7297	,	_
42-33	7298-7307	resampled	_
42-34	7308-7310	to	_
42-35	7311-7314	512	_
42-36	7315-7316	×	_
42-37	7317-7320	512	_
42-38	7321-7322	;	_
42-39	7323-7325	TR	_
42-40	7326-7327	=	_
42-41	7328-7333	1,700	_
42-42	7334-7336	ms	_
42-43	7337-7338	;	_
42-44	7339-7341	TE	_
42-45	7342-7343	=	_
42-46	7344-7348	3.96	_
42-47	7349-7351	ms	_
42-48	7352-7353	;	_
42-49	7354-7357	FOV	_
42-50	7358-7359	=	_
42-51	7360-7363	246	_
42-52	7364-7366	mm	_
42-53	7367-7368	;	_
42-54	7369-7371	FA	_
42-55	7372-7373	=	_
42-56	7374-7377	15°	_
42-57	7378-7379	;	_
42-58	7380-7385	slice	_
42-59	7386-7395	thickness	_
42-60	7396-7397	=	_
42-61	7398-7402	1.17	_
42-62	7403-7405	mm	_
42-63	7406-7407	;	_
42-64	7408-7414	native	_
42-65	7415-7417	in	_
42-66	7418-7423	plane	_
42-67	7424-7434	resolution	_
42-68	7435-7436	=	_
42-69	7437-7441	0.96	_
42-70	7442-7444	mm	_
42-71	7445-7446	)	_
42-72	7447-7448	.	_

Text=Eight images were discarded due to severe motion artifacts identified by visual inspection.
43-1	7449-7454	Eight	_
43-2	7455-7461	images	_
43-3	7462-7466	were	_
43-4	7467-7476	discarded	_
43-5	7477-7480	due	_
43-6	7481-7483	to	_
43-7	7484-7490	severe	_
43-8	7491-7497	motion	_
43-9	7498-7507	artifacts	_
43-10	7508-7518	identified	_
43-11	7519-7521	by	_
43-12	7522-7528	visual	_
43-13	7529-7539	inspection	_
43-14	7540-7541	.	_

Text=The resulting images comprised the data described above and analyzed as follows.
44-1	7542-7545	The	_
44-2	7546-7555	resulting	_
44-3	7556-7562	images	_
44-4	7563-7572	comprised	_
44-5	7573-7576	the	_
44-6	7577-7581	data	_
44-7	7582-7591	described	_
44-8	7592-7597	above	_
44-9	7598-7601	and	_
44-10	7602-7610	analyzed	_
44-11	7611-7613	as	_
44-12	7614-7621	follows	_
44-13	7622-7623	.	_

Text=MRI data preprocessing We used the Freesurfer 6.0 toolbox for data preprocessing with additional tool for hippocampal subfields segmentation (recon‐all –all –hippocampal‐subfields‐T1 command) (Iglesias et al., 2015).
45-1	7624-7627	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
45-2	7628-7632	data	_
45-3	7633-7646	preprocessing	_
45-4	7647-7649	We	_
45-5	7650-7654	used	_
45-6	7655-7658	the	_
45-7	7659-7669	Freesurfer	_
45-8	7670-7673	6.0	_
45-9	7674-7681	toolbox	_
45-10	7682-7685	for	_
45-11	7686-7690	data	_
45-12	7691-7704	preprocessing	_
45-13	7705-7709	with	_
45-14	7710-7720	additional	_
45-15	7721-7725	tool	_
45-16	7726-7729	for	_
45-17	7730-7741	hippocampal	_
45-18	7742-7751	subfields	_
45-19	7752-7764	segmentation	_
45-20	7765-7766	(	_
45-21	7767-7776	recon‐all	_
45-22	7777-7781	–all	_
45-23	7782-7807	–hippocampal‐subfields‐T1	_
45-24	7808-7815	command	_
45-25	7816-7817	)	_
45-26	7818-7819	(	_
45-27	7820-7828	Iglesias	_
45-28	7829-7831	et	_
45-29	7832-7835	al.	_
45-30	7836-7837	,	_
45-31	7838-7842	2015	_
45-32	7843-7844	)	_
45-33	7845-7846	.	_

Text=The output of the preprocessing contained an information of the hippocampal subfields volumes, namely parasubiculum, presubiculum, subiculum, CA1, CA3, CA4, GC‐DG, HATA, fimbria, molecular layer HP, fissure and tail as well as an estimate of the total intracranial volume (TIV).
46-1	7847-7850	The	_
46-2	7851-7857	output	_
46-3	7858-7860	of	_
46-4	7861-7864	the	_
46-5	7865-7878	preprocessing	_
46-6	7879-7888	contained	_
46-7	7889-7891	an	_
46-8	7892-7903	information	_
46-9	7904-7906	of	_
46-10	7907-7910	the	_
46-11	7911-7922	hippocampal	_
46-12	7923-7932	subfields	_
46-13	7933-7940	volumes	_
46-14	7941-7942	,	_
46-15	7943-7949	namely	_
46-16	7950-7963	parasubiculum	_
46-17	7964-7965	,	_
46-18	7966-7978	presubiculum	_
46-19	7979-7980	,	_
46-20	7981-7990	subiculum	_
46-21	7991-7992	,	_
46-22	7993-7996	CA1	_
46-23	7997-7998	,	_
46-24	7999-8002	CA3	_
46-25	8003-8004	,	_
46-26	8005-8008	CA4	_
46-27	8009-8010	,	_
46-28	8011-8016	GC‐DG	_
46-29	8017-8018	,	_
46-30	8019-8023	HATA	_
46-31	8024-8025	,	_
46-32	8026-8033	fimbria	_
46-33	8034-8035	,	_
46-34	8036-8045	molecular	_
46-35	8046-8051	layer	_
46-36	8052-8054	HP	_
46-37	8055-8056	,	_
46-38	8057-8064	fissure	_
46-39	8065-8068	and	_
46-40	8069-8073	tail	_
46-41	8074-8076	as	_
46-42	8077-8081	well	_
46-43	8082-8084	as	_
46-44	8085-8087	an	_
46-45	8088-8096	estimate	_
46-46	8097-8099	of	_
46-47	8100-8103	the	_
46-48	8104-8109	total	_
46-49	8110-8122	intracranial	_
46-50	8123-8129	volume	_
46-51	8130-8131	(	_
46-52	8132-8135	TIV	_
46-53	8136-8137	)	_
46-54	8138-8139	.	_

Text=The subfield volumes were corrected for age and gender effects using linear regression and for variability in head volume using normalization by TIV.
47-1	8140-8143	The	_
47-2	8144-8152	subfield	_
47-3	8153-8160	volumes	_
47-4	8161-8165	were	_
47-5	8166-8175	corrected	_
47-6	8176-8179	for	_
47-7	8180-8183	age	_
47-8	8184-8187	and	_
47-9	8188-8194	gender	_
47-10	8195-8202	effects	_
47-11	8203-8208	using	_
47-12	8209-8215	linear	_
47-13	8216-8226	regression	_
47-14	8227-8230	and	_
47-15	8231-8234	for	_
47-16	8235-8246	variability	_
47-17	8247-8249	in	_
47-18	8250-8254	head	_
47-19	8255-8261	volume	_
47-20	8262-8267	using	_
47-21	8268-8281	normalization	_
47-22	8282-8284	by	_
47-23	8285-8288	TIV	_
47-24	8289-8290	.	_

Text=We refer to these values as corrected subfield volumes (CSV).
48-1	8291-8293	We	_
48-2	8294-8299	refer	_
48-3	8300-8302	to	_
48-4	8303-8308	these	_
48-5	8309-8315	values	_
48-6	8316-8318	as	_
48-7	8319-8328	corrected	_
48-8	8329-8337	subfield	_
48-9	8338-8345	volumes	_
48-10	8346-8347	(	_
48-11	8348-8351	CSV	_
48-12	8352-8353	)	_
48-13	8354-8355	.	_

Text=Statistics The purpose of the study was to map GMV within distinctive hippocampal subfields, and to perform comparisons in these measures of GMV among the DV+, DV−, SCH, and MTLE groups.
49-1	8356-8366	Statistics	_
49-2	8367-8370	The	_
49-3	8371-8378	purpose	_
49-4	8379-8381	of	_
49-5	8382-8385	the	_
49-6	8386-8391	study	_
49-7	8392-8395	was	_
49-8	8396-8398	to	_
49-9	8399-8402	map	_
49-10	8403-8406	GMV	_
49-11	8407-8413	within	_
49-12	8414-8425	distinctive	_
49-13	8426-8437	hippocampal	_
49-14	8438-8447	subfields	_
49-15	8448-8449	,	_
49-16	8450-8453	and	_
49-17	8454-8456	to	_
49-18	8457-8464	perform	_
49-19	8465-8476	comparisons	_
49-20	8477-8479	in	_
49-21	8480-8485	these	_
49-22	8486-8494	measures	_
49-23	8495-8497	of	_
49-24	8498-8501	GMV	_
49-25	8502-8507	among	_
49-26	8508-8511	the	_
49-27	8512-8515	DV+	_
49-28	8516-8517	,	_
49-29	8518-8521	DV−	_
49-30	8522-8523	,	_
49-31	8524-8527	SCH	_
49-32	8528-8529	,	_
49-33	8530-8533	and	_
49-34	8534-8538	MTLE	_
49-35	8539-8545	groups	_
49-36	8546-8547	.	_

Text=We carried out two statistical tests with the STATISTICA 12 (StatSoft, Inc., USA).
50-1	8548-8550	We	_
50-2	8551-8558	carried	_
50-3	8559-8562	out	_
50-4	8563-8566	two	_
50-5	8567-8578	statistical	_
50-6	8579-8584	tests	_
50-7	8585-8589	with	_
50-8	8590-8593	the	_
50-9	8594-8604	STATISTICA	_
50-10	8605-8607	12	_
50-11	8608-8609	(	_
50-12	8610-8618	StatSoft	_
50-13	8619-8620	,	_
50-14	8621-8625	Inc.	_
50-15	8626-8627	,	_
50-16	8628-8631	USA	_
50-17	8632-8633	)	_
50-18	8634-8635	.	_

Text=Subfield specific GMV decrease To reveal subfield specific GMV change in DV+, SCH, and MTLE group relative to the DV− group, we performed Mann‐Whitney tests on CSV for each subfield and group (DV+, SCH and MTLE vs. DV−).
51-1	8636-8644	Subfield	_
51-2	8645-8653	specific	_
51-3	8654-8657	GMV	_
51-4	8658-8666	decrease	_
51-5	8667-8669	To	_
51-6	8670-8676	reveal	_
51-7	8677-8685	subfield	_
51-8	8686-8694	specific	_
51-9	8695-8698	GMV	_
51-10	8699-8705	change	_
51-11	8706-8708	in	_
51-12	8709-8712	DV+	_
51-13	8713-8714	,	_
51-14	8715-8718	SCH	_
51-15	8719-8720	,	_
51-16	8721-8724	and	_
51-17	8725-8729	MTLE	_
51-18	8730-8735	group	_
51-19	8736-8744	relative	_
51-20	8745-8747	to	_
51-21	8748-8751	the	_
51-22	8752-8755	DV−	_
51-23	8756-8761	group	_
51-24	8762-8763	,	_
51-25	8764-8766	we	_
51-26	8767-8776	performed	_
51-27	8777-8789	Mann‐Whitney	_
51-28	8790-8795	tests	_
51-29	8796-8798	on	_
51-30	8799-8802	CSV	_
51-31	8803-8806	for	_
51-32	8807-8811	each	_
51-33	8812-8820	subfield	_
51-34	8821-8824	and	_
51-35	8825-8830	group	_
51-36	8831-8832	(	_
51-37	8833-8836	DV+	_
51-38	8837-8838	,	_
51-39	8839-8842	SCH	_
51-40	8843-8846	and	_
51-41	8847-8851	MTLE	_
51-42	8852-8855	vs.	_
51-43	8856-8859	DV−	_
51-44	8860-8861	)	_
51-45	8862-8863	.	_

Text=The significance level was set to p <.05.
52-1	8864-8867	The	_
52-2	8868-8880	significance	_
52-3	8881-8886	level	_
52-4	8887-8890	was	_
52-5	8891-8894	set	_
52-6	8895-8897	to	_
52-7	8898-8899	p	_
52-8	8900-8901	<	_
52-9	8902-8905	.05	_
52-10	8906-8907	.	_

Text=Spatial distribution of GMV decrease We computed median of the CSV volumes (mCSV) across subjects for each group and subfield.
53-1	8908-8915	Spatial	_
53-2	8916-8928	distribution	_
53-3	8929-8931	of	_
53-4	8932-8935	GMV	_
53-5	8936-8944	decrease	_
53-6	8945-8947	We	_
53-7	8948-8956	computed	_
53-8	8957-8963	median	_
53-9	8964-8966	of	_
53-10	8967-8970	the	_
53-11	8971-8974	CSV	_
53-12	8975-8982	volumes	_
53-13	8983-8984	(	_
53-14	8985-8989	mCSV	_
53-15	8990-8991	)	_
53-16	8992-8998	across	_
53-17	8999-9007	subjects	_
53-18	9008-9011	for	_
53-19	9012-9016	each	_
53-20	9017-9022	group	_
53-21	9023-9026	and	_
53-22	9027-9035	subfield	_
53-23	9036-9037	.	_

Text=To identify which patient group resembles more the DV+ group considering the spatial pattern of GMV deviations from DV− we further computed the deviation of mCSV between DV+/MTLE/SCH and DV− (dmSCV).
54-1	9038-9040	To	_
54-2	9041-9049	identify	_
54-3	9050-9055	which	_
54-4	9056-9063	patient	_
54-5	9064-9069	group	_
54-6	9070-9079	resembles	_
54-7	9080-9084	more	_
54-8	9085-9088	the	_
54-9	9089-9092	DV+	_
54-10	9093-9098	group	_
54-11	9099-9110	considering	_
54-12	9111-9114	the	_
54-13	9115-9122	spatial	_
54-14	9123-9130	pattern	_
54-15	9131-9133	of	_
54-16	9134-9137	GMV	_
54-17	9138-9148	deviations	_
54-18	9149-9153	from	_
54-19	9154-9157	DV−	_
54-20	9158-9160	we	_
54-21	9161-9168	further	_
54-22	9169-9177	computed	_
54-23	9178-9181	the	_
54-24	9182-9191	deviation	_
54-25	9192-9194	of	_
54-26	9195-9199	mCSV	_
54-27	9200-9207	between	_
54-28	9208-9220	DV+/MTLE/SCH	_
54-29	9221-9224	and	_
54-30	9225-9228	DV−	_
54-31	9229-9230	(	_
54-32	9231-9236	dmSCV	_
54-33	9237-9238	)	_
54-34	9239-9240	.	_

Text=The dmCSV patterns were assessed using Pearson correlation coefficient, that is, we computed correlation coefficient based on dmSCV for DV+ vs MTLE in affected hippocampus and DV+ vs SCH in both‐sided hippocampi.
55-1	9241-9244	The	_
55-2	9245-9250	dmCSV	_
55-3	9251-9259	patterns	_
55-4	9260-9264	were	_
55-5	9265-9273	assessed	_
55-6	9274-9279	using	_
55-7	9280-9287	Pearson	_
55-8	9288-9299	correlation	_
55-9	9300-9311	coefficient	_
55-10	9312-9313	,	_
55-11	9314-9318	that	_
55-12	9319-9321	is	_
55-13	9322-9323	,	_
55-14	9324-9326	we	_
55-15	9327-9335	computed	_
55-16	9336-9347	correlation	_
55-17	9348-9359	coefficient	_
55-18	9360-9365	based	_
55-19	9366-9368	on	_
55-20	9369-9374	dmSCV	_
55-21	9375-9378	for	_
55-22	9379-9382	DV+	_
55-23	9383-9385	vs	_
55-24	9386-9390	MTLE	_
55-25	9391-9393	in	_
55-26	9394-9402	affected	_
55-27	9403-9414	hippocampus	_
55-28	9415-9418	and	_
55-29	9419-9422	DV+	_
55-30	9423-9425	vs	_
55-31	9426-9429	SCH	_
55-32	9430-9432	in	_
55-33	9433-9443	both‐sided	_
55-34	9444-9454	hippocampi	_
55-35	9455-9456	.	_

Text=The significance level of correlation coefficients was set to p <.05.
56-1	9457-9460	The	_
56-2	9461-9473	significance	_
56-3	9474-9479	level	_
56-4	9480-9482	of	_
56-5	9483-9494	correlation	_
56-6	9495-9507	coefficients	_
56-7	9508-9511	was	_
56-8	9512-9515	set	_
56-9	9516-9518	to	_
56-10	9519-9520	p	_
56-11	9521-9522	<	_
56-12	9523-9526	.05	_
56-13	9527-9528	.	_

